Reducing Symptom Burden Through Physical Exercise in Melanoma Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversität Duisburg-Essen

About this trial

The aim of the clinical trial is to determine whether regular exercise can reduce fatigue in adult patients with stage IIb-IV melanoma undergoing immunotherapy or targeted therapy. Additionally, we will investigate whether a supervised exercise program improves patients' quality of life, cognitive skills, and physical fitness compared to a control group without structured exercise. We will also examine other health outcomes and various blood parameters, such as interleukins and metabolites, to understand how regular activity can affect metabolism and immune function.

After the initial assessment at the clinic, patients will be randomly assigned to two groups. Those in the intervention group will participate in a 12-week exercise program, which includes a 60-minute personalized and supervised online training session twice a week. In weeks 3, 6, and 9, one training session will be held at the clinic. Furthermore, patients in the intervention group are encouraged to complete a self-administered 20-minute exercise session once a week. The control group will not receive a supervised exercise program. Following the 12-week intervention period, another assessment will be conducted at the clinic. All patients will then enter a 6-week follow-up phase, during which neither group will receive supervised exercise training. After this follow-up phase, a final assessment of all outcomes will take place at the clinic.

Eligibility criteria

Qualifiers

patients ≥ 18 years with malignant melanoma (Stage IIb - IV) receiving adjuvant or palliative immunotherapy or targeted therapy

patients with ECOG level 0-2

patients already on the same treatment protocol for at least 3 months and no more than 9 months

sufficient knowledge of German

Disqualifiers

confirmation of contraindications for physical exercise by the attending physician (e.g. fracture risk in the case of bone metastases)

untreated, symptomatic, known brain metastases

severe neurological or cardiac impairment according to ACSM criteria

confirmation of respiratory insufficiency by the attending physician

Trial design

Treatments tested in this trial

  • Supervised 12-week Resistance and Endurance Exercise Program

Treatment groups

104 Participants
are divided into 2 treatment groups

Sponsors and collaborators